Bayer’s Nubeqa Improves Overall Survival in Metastatic Prostate Cancer

Bayer’s phase 3 study of Nubeqa (darolutamide) in combination with androgen-deprivation therapy (ADT) and docetaxel for patients with metastatic hormone-sensitive prostate cancer has hit its primary endpoint, showing that the combo improved overall survival compared to docetaxel and ADT alone.
Source: Drug Industry Daily